Zanidatamab plus chemo before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed stage 2 or 3 breast cancer that is HER2-positive.
- The tumor is at least 2 cm in size (or the largest tumor is HER2-positive if you have multiple tumors).
- You have not had any prior treatment for invasive breast cancer, such as surgery, chemotherapy, or radiation.
- You are able to undergo mastectomy or breast-conserving surgery after the study treatment.
- Your heart function, organ function, and overall health are good enough for the study.
- You do not have metastatic (stage 4) or bilateral breast cancer, or active infections like hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.